These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19426159)

  • 1. CXCL16 and oxLDL are induced in the onset of diabetic nephropathy.
    Gutwein P; Abdel-Bakky MS; Doberstein K; Schramme A; Beckmann J; Schaefer L; Amann K; Doller A; Kämpfer-Kolb N; Abdel-Aziz AA; El Sayed el SM; Pfeilschifter J
    J Cell Mol Med; 2009 Sep; 13(9B):3809-25. PubMed ID: 19426159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein.
    Gutwein P; Abdel-Bakky MS; Schramme A; Doberstein K; Kämpfer-Kolb N; Amann K; Hauser IA; Obermüller N; Bartel C; Abdel-Aziz AA; El Sayed el SM; Pfeilschifter J
    Am J Pathol; 2009 Jun; 174(6):2061-72. PubMed ID: 19435795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. oxLDL-induced lipid accumulation in glomerular podocytes: role of IFN-γ, CXCL16, and ADAM10.
    Wang L; Sun S; Zhou A; Yao X; Wang Y
    Cell Biochem Biophys; 2014 Sep; 70(1):529-38. PubMed ID: 24752304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atherogenic lipids induce high-density lipoprotein uptake and cholesterol efflux in human macrophages by up-regulating transmembrane chemokine CXCL16 without engaging CXCL16-dependent cell adhesion.
    Barlic J; Zhu W; Murphy PM
    J Immunol; 2009 Jun; 182(12):7928-36. PubMed ID: 19494317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney.
    Schramme A; Abdel-Bakky MS; Gutwein P; Obermüller N; Baer PC; Hauser IA; Ludwig A; Gauer S; Schäfer L; Sobkowiak E; Altevogt P; Koziolek M; Kiss E; Gröne HJ; Tikkanen R; Goren I; Radeke H; Pfeilschifter J
    Kidney Int; 2008 Aug; 74(3):328-38. PubMed ID: 18480749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. oxLDL promotes podocyte migration by regulating CXCL16, ADAM10 and ACTN4.
    Chen Y; Wang Z; Li Q; Yu L; Zhu Y; Wang J; Sun S
    Mol Med Rep; 2020 Sep; 22(3):1976-1984. PubMed ID: 32705248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16.
    Gough PJ; Garton KJ; Wille PT; Rychlewski M; Dempsey PJ; Raines EW
    J Immunol; 2004 Mar; 172(6):3678-85. PubMed ID: 15004171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.
    Gutwein P; Schramme A; Sinke N; Abdel-Bakky MS; Voss B; Obermüller N; Doberstein K; Koziolek M; Fritzsche F; Johannsen M; Jung K; Schaider H; Altevogt P; Ludwig A; Pfeilschifter J; Kristiansen G
    Eur J Cancer; 2009 Feb; 45(3):478-89. PubMed ID: 19070478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10.
    Abel S; Hundhausen C; Mentlein R; Schulte A; Berkhout TA; Broadway N; Hartmann D; Sedlacek R; Dietrich S; Muetze B; Schuster B; Kallen KJ; Saftig P; Rose-John S; Ludwig A
    J Immunol; 2004 May; 172(10):6362-72. PubMed ID: 15128827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of CXCL16 and its processing metalloproteinases ADAM10 and ADAM17 in the proliferation and migration of human mesangial cells.
    Schramme A; Abdel-Bakky MS; Kämpfer-Kolb N; Pfeilschifter J; Gutwein P
    Biochem Biophys Res Commun; 2008 May; 370(2):311-6. PubMed ID: 18373975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by alpha- and gamma-secretases.
    Schulte A; Schulz B; Andrzejewski MG; Hundhausen C; Mletzko S; Achilles J; Reiss K; Paliga K; Weber C; John SR; Ludwig A
    Biochem Biophys Res Commun; 2007 Jun; 358(1):233-40. PubMed ID: 17467666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes.
    Hundhausen C; Schulte A; Schulz B; Andrzejewski MG; Schwarz N; von Hundelshausen P; Winter U; Paliga K; Reiss K; Saftig P; Weber C; Ludwig A
    J Immunol; 2007 Jun; 178(12):8064-72. PubMed ID: 17548644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive expression and regulated release of the transmembrane chemokine CXCL16 in human and murine skin.
    Scholz F; Schulte A; Adamski F; Hundhausen C; Mittag J; Schwarz A; Kruse ML; Proksch E; Ludwig A
    J Invest Dermatol; 2007 Jun; 127(6):1444-55. PubMed ID: 17363916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury.
    Okamura DM; López-Guisa JM; Koelsch K; Collins S; Eddy AA
    Am J Physiol Renal Physiol; 2007 Aug; 293(2):F575-85. PubMed ID: 17537985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enoxaparin prevents CXCL16/ADAM10-mediated cisplatin renal toxicity: Role of the coagulation system and the transcriptional factor NF-κB.
    Aboyoussef AM; Abdel-Sattar AR; Abdel-Bakky MS; Messiha BAS
    Life Sci; 2021 Apr; 270():119120. PubMed ID: 33545204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation.
    Izquierdo MC; Sanz AB; Mezzano S; Blanco J; Carrasco S; Sanchez-Niño MD; Benito-Martín A; Ruiz-Ortega M; Egido J; Ortiz A
    Kidney Int; 2012 Jun; 81(11):1098-107. PubMed ID: 22278019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis.
    Aslanian AM; Charo IF
    Circulation; 2006 Aug; 114(6):583-90. PubMed ID: 16880330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the CXCL16/CXCR6 Pathway by Inflammation Contributes to Atherosclerosis in Patients with End-stage Renal Disease.
    Hu ZB; Chen Y; Gong YX; Gao M; Zhang Y; Wang GH; Tang RN; Liu H; Liu BC; Ma KL
    Int J Med Sci; 2016; 13(11):858-867. PubMed ID: 27877078
    [No Abstract]   [Full Text] [Related]  

  • 19. Human P2X7 receptor activation induces the rapid shedding of CXCL16.
    Pupovac A; Foster CM; Sluyter R
    Biochem Biophys Res Commun; 2013 Mar; 432(4):626-31. PubMed ID: 23428418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity.
    Gooden MJ; Wiersma VR; Boerma A; Leffers N; Boezen HM; ten Hoor KA; Hollema H; Walenkamp AM; Daemen T; Nijman HW; Bremer E
    Br J Cancer; 2014 Mar; 110(6):1535-44. PubMed ID: 24518602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.